#USA #Salt Lake City #pharmacogenomics #Oxford Nanopore #Wasatch BioLabs

Wasatch BioLabs Expands Service Portfolio with Oxford Nanopore Assays

In a significant development for genomic research, Wasatch BioLabs (WBL), the leading U.S. provider of long-read sequencing services and a subsidiary of Renew Biotechnologies, has announced the incorporation of three new Oxford Nanopore-developed research-use-only (RUO) assays into its service portfolio. The new offerings include a Pharmacogenomics (PgX) panel, Telomere Sequencing, and mRNA Vaccine Quality Control.

Headquartered in Salt Lake City, Utah, in a substantial 20,000 square foot CLIA-registered laboratory, Wasatch BioLabs combines the innovative assays from Oxford Nanopore with its extensive expertise in long-read sequencing. This integration aims to provide actionable insights and data clarity that can significantly benefit researchers in various fields.

Enhancements in Pharmacogenomics

The newly introduced Pharmacogenomics panel developed by Oxford Nanopore is designed to deliver comprehensive gene coverage, which notably includes repeats, structural variations, and hybrid alleles that traditional short-read methods typically overlook. By offering this panel as a service, WBL empowers researchers to generate comprehensive pharmacogenomic profiles, thus facilitating rapid turnaround with integrated bioinformatics support. This innovation aids in meeting specific study considerations and regulatory standards, thereby enhancing the precision medicine landscape and strengthening drug development pipelines.

Telomere Sequencing Breakthrough

WBL is also excited to offer Telomere Sequencing, a state-of-the-art assay that provides molecule-level resolution vital for understanding telomere length distributions and subtelomeric methylation across individual chromosome arms. This technology is particularly beneficial for oncology, aging, and rare disease studies where subtle dynamics of telomeres can have profound biological implications. The high precision of this assay allows researchers to integrate telomere metrics into longitudinal studies and translational models with improved consistency.

Quality Control for mRNA Vaccines

In light of the increasing importance of mRNA vaccination technology, Wasatch BioLabs has introduced a dedicated mRNA Vaccine Quality Control service. Utilizing long reads and single-molecule resolution without amplification artifacts, the QC service delivers a detailed and accurate representation of mRNA constructs from early development stages through final lot release and stability evaluations. This streamlined workflow guarantees preservation of critical features such as poly(A) tails, structural diversity, and overall integrity—essential aspects needed to confirm product quality and ensure regulatory readiness.

Expanding Applications and Access

The integration of these new assays marks a significant milestone for Wasatch BioLabs, enabling it to substantially enhance its support for BioPharma and Biotech teams across a myriad of applications. This spans drug response investigations, telomere biology research, and mRNA vaccine development. With Oxford Nanopore's assays running through WBL's high-capacity infrastructure and specialized bioinformatics pipelines, researchers will now have access to advanced long-read workflows crafted to impact both discovery and translational research effectively.

About Wasatch BioLabs

Wasatch BioLabs stands as the largest sequencing service provider in the United States exclusively focused on long-read sequencing technology. Operating out of Salt Lake City, the company is renowned for its state-of-the-art laboratories, quality audit systems, and high-throughput processing capacity. Partnering with BioPharma, academic institutes, and biotech companies, WBL delivers comprehensive sequencing solutions across a variety of genomic analysis applications.

For additional details and insights on Wasatch BioLabs and its expanding services, visit Wasatch BioLabs.